Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOXAPARIN SODIUM (PRESERVATIVE FREE) vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients at risk for thromboembolic complications,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) with aspirin,Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Mild to moderate pain,Pain accompanied by fever
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is 4.5 hours after subcutaneous administration based on anti-Factor Xa activity; prolonged to 6-7 hours in renal impairment (Cr Cl <30 m L/min).
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Enoxaparin is primarily metabolized in the liver via desulfation and depolymerization, with some renal clearance. It does not rely on cytochrome P450 enzymes.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Renal excretion of anti-Factor Xa activity accounts for approximately 40% of total clearance; a small fraction undergoes biliary/fecal elimination (<10%).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Approximately 92-95% bound to antithrombin III (ATIII) and other plasma proteins.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
0.10-0.13 L/kg; confined primarily to intravascular space, indicating limited extravascular distribution.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Subcutaneous: Approximately 92-100% absorbed; intravenous administration yields 100% bioavailability.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis: 30 mg subcutaneously once daily. Not recommended if Cr Cl <15 m L/min.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No specific dose adjustment guidelines for hepatic impairment; use with caution in severe hepatic impairment due to increased bleeding risk.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Dose based on age: neonates and infants <2 months: 1.5 mg/kg subcutaneously every 12 hours; children ≥2 months: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Increased risk of bleeding, especially in elderly ≥75 years; consider dose reduction and monitor renal function and anti-Xa levels. For treatment in elderly ≥75 years: 1 mg/kg subcutaneously every 12 hours; no routine dose reduction but caution advised.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Spinal/epidural hematomas may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis. Risk is increased by use of indwelling epidural catheters, concomitant use of other anticoagulants, or history of spinal surgery/deformity. Monitor for signs of neurological impairment and manage emergently.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Risk of spinal/epidural hematoma with neuraxial procedures,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or concurrent use of anticoagulants/antiplatelets,Heparin-induced thrombocytopenia (HIT) possible; monitor platelet counts,Use with caution in patients with bleeding disorders, uncontrolled hypertension, or recent surgery,Not interchangeable with other heparins (unit-for-unit)
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Active major bleeding,History of immune-mediated heparin-induced thrombocytopenia (HIT) within 100 days,Known hypersensitivity to enoxaparin, heparin, or pork products,Concomitant use with other anticoagulants (except under close monitoring)
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No specific food restrictions. Avoid excessive consumption of alcohol (may increase bleeding risk). Maintain adequate vitamin K intake, but avoid sudden large changes.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no known teratogenic effects. Second trimester: no known fetal harm. Third trimester: risk of maternal hemorrhage, which may indirectly affect fetus; use with caution.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Enoxaparin is excreted into breast milk in negligible amounts. The milk-to-plasma ratio is approximately 0.04. It is considered compatible with breastfeeding due to poor oral bioavailability in the infant. No adverse effects reported.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Pregnancy increases plasma volume and renal clearance, leading to decreased peak anti-Xa levels and half-life. Dose adjustments may be needed to maintain therapeutic levels, especially in the third trimester. Weight-based dosing is recommended and may require upward titration. Anti-Xa monitoring is advised to guide dose adjustments. No standard fixed dose adjustment; individualize based on anti-Xa levels and clinical response.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Enoxaparin is a low molecular weight heparin (LMWH) preferred over unfractionated heparin for VTE prophylaxis due to predictable pharmacokinetics and no need for routine a PTT monitoring. Adjust dose for renal impairment (Cr Cl <30 m L/min). Protamine sulfate partially reverses (about 60%) its anticoagulant effect. Monitor for signs of bleeding, especially in elderly, low body weight (<45 kg), or those on antiplatelet agents. Avoid intramuscular injections. Spinal/epidural hematoma risk with neuraxial anesthesia; remove catheter at least 12 hours after last dose (24 hours if therapeutic dose).
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Take exactly as prescribed; do not skip doses.,Inject subcutaneously in the fatty tissue of the abdomen, alternating sides.,Do not rub the injection site after administration.,Report any unusual bleeding or bruising, blood in urine or stool, or coughing up blood.,Avoid aspirin or NSAIDs unless directed by your doctor.,Seek immediate medical attention for severe headache, back pain, or neurological symptoms (signs of spinal hematoma).,Inform all healthcare providers you are taking this medication, especially before surgery or dental procedures.,Do not stop abruptly without consulting your doctor.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOXAPARIN SODIUM (PRESERVATIVE FREE) vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
ENOXAPARIN SODIUM (PRESERVATIVE FREE) is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOXAPARIN SODIUM (PRESERVATIVE FREE) and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOXAPARIN SODIUM (PRESERVATIVE FREE) is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOXAPARIN SODIUM (PRESERVATIVE FREE) and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOXAPARIN SODIUM (PRESERVATIVE FREE) is classified as Category A/B. Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no kno. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.